Interesting. I do note in the limitations two things:
1. in the canaloplasty group, there was a higher number of secondary glaucoma patients, but no mention of the percentage. What if over half were? Seems to be quite a serious limitation to the results.
2. A large number of patients that had the canaloplasty surgery did not return for the follow-up check (likely due to success and no complications), and then removed from the study - resulting a lower percentage of success. I believe it was 30 - if 20 had been successful, the whole thesis is weakened considerably.
Let me know if I have misunderstood the impact of those limitations of the study.
Nova Eye Medical (EYE) Discussion, page-898
-
- There are more pages in this discussion • 2,290 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.79M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 16.0¢ | $38.96K | 239.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4819 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 79620 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |